Wellington Management Group LLP Takes $379,000 Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Wellington Management Group LLP purchased a new position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 65,633 shares of the biopharmaceutical company’s stock, valued at approximately $379,000. Wellington Management Group LLP owned approximately 0.25% of Inovio Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares during the period. MetLife Investment Management LLC raised its position in Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 8,546 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Inovio Pharmaceuticals in the second quarter worth about $82,000. Signature Estate & Investment Advisors LLC purchased a new position in shares of Inovio Pharmaceuticals during the second quarter valued at approximately $88,000. Finally, American Century Companies Inc. grew its stake in shares of Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ INO opened at $1.84 on Friday. Inovio Pharmaceuticals, Inc. has a twelve month low of $1.74 and a twelve month high of $14.75. The firm has a market cap of $48.02 million, a PE ratio of -0.53 and a beta of 0.75. The business has a fifty day simple moving average of $4.53 and a two-hundred day simple moving average of $6.87.

Analyst Ratings Changes

INO has been the subject of a number of research analyst reports. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Monday, November 18th. Royal Bank of Canada reduced their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. Finally, Oppenheimer lowered their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $38.00.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.